Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

Exclusion Criteria

• •Previous use of anthracycline.
• •Hypersensitivity to any mineralocorticoid receptor antagonists
• •Symptoms of heart failure (exertional dyspnea, orthopnea, nocturnal paroxysmal dyspnea, and pulmonary or systemic congestion)
• •Left ventricular ejection fraction (LVEF) \< 45%
• •Previous diagnosis of cardiomyopathy, coronary artery disease, or moderate to severe mitral or aortic disease
• •Renal insufficiency defined as an estimated glomerular filtration rate \< 30 ml/min/m2
• •Hyperkalemia, defined as serum potassium ≥ 5.0 mmol/L
• •Chronic liver disease, defined aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values more than 3 times the upper limit of normal
• •Current participation in another study